These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 34472037)

  • 1. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
    Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
    Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
    Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

  • 11. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of CAR-NK Cells Targeting cSCC-Specific Antigens for Precision Immunotherapy.
    Tayanloo-Beik A; Roudsari PP; Aghayan H; Arjmand R; Rezaei-Tavirani M; Larijani B; Rajaeinejad M; Mosaed R; Arjmand B
    Methods Mol Biol; 2024; 2849():253-263. PubMed ID: 38095836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
    Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
    Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.